Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus

Yusuke Tanigawara, Reiko Sato, Kunihiko Morita, Mitsuo Kaku, Naoki Aikawa, Kihachiro Shimizu

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CLCR), age, and body weight (WT), as expressed by CL (liter/h) = 0.0319CLCR + (26.5/age) (CLCR < 80 ml/min) and CL (liter/h) = 0.0130 CLCR + 0.0342WT + (26.5/age) (CLCR ≥ 80 ml/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19% greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.

Original languageEnglish
Pages (from-to)3754-3762
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume50
Issue number11
DOIs
Publication statusPublished - 2006 Nov

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Pharmacokinetics
Population
Aminoglycosides
Dibekacin
Pharmaceutical Preparations
habekacin
Volunteers
Creatinine
Sepsis
Pneumonia
Patient Care
Healthy Volunteers
Japan
Body Weight
Weights and Measures
Therapeutics
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. / Tanigawara, Yusuke; Sato, Reiko; Morita, Kunihiko; Kaku, Mitsuo; Aikawa, Naoki; Shimizu, Kihachiro.

In: Antimicrobial Agents and Chemotherapy, Vol. 50, No. 11, 11.2006, p. 3754-3762.

Research output: Contribution to journalArticle

Tanigawara, Yusuke ; Sato, Reiko ; Morita, Kunihiko ; Kaku, Mitsuo ; Aikawa, Naoki ; Shimizu, Kihachiro. / Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. In: Antimicrobial Agents and Chemotherapy. 2006 ; Vol. 50, No. 11. pp. 3754-3762.
@article{b917a1f5db8a4a63ab4c0e5e6ae7441e,
title = "Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus",
abstract = "Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CLCR), age, and body weight (WT), as expressed by CL (liter/h) = 0.0319CLCR + (26.5/age) (CLCR < 80 ml/min) and CL (liter/h) = 0.0130 CLCR + 0.0342WT + (26.5/age) (CLCR ≥ 80 ml/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19{\%} greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.",
author = "Yusuke Tanigawara and Reiko Sato and Kunihiko Morita and Mitsuo Kaku and Naoki Aikawa and Kihachiro Shimizu",
year = "2006",
month = "11",
doi = "10.1128/AAC.00420-05",
language = "English",
volume = "50",
pages = "3754--3762",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus

AU - Tanigawara, Yusuke

AU - Sato, Reiko

AU - Morita, Kunihiko

AU - Kaku, Mitsuo

AU - Aikawa, Naoki

AU - Shimizu, Kihachiro

PY - 2006/11

Y1 - 2006/11

N2 - Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CLCR), age, and body weight (WT), as expressed by CL (liter/h) = 0.0319CLCR + (26.5/age) (CLCR < 80 ml/min) and CL (liter/h) = 0.0130 CLCR + 0.0342WT + (26.5/age) (CLCR ≥ 80 ml/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19% greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.

AB - Arbekacin, a derivative of dibekacin, is an aminoglycoside developed and widely used in Japan for the treatment of patients infected with methicillin-resistant Staphylococcus aureus (MRSA). The population pharmacokinetics of arbekacin was investigated in the Japanese, using 353 patients infected with MRSA and 50 healthy or renally impaired volunteers. The age of the study population ranged from 8 to 95 years, and weight ranged from 10.8 to 107 kg. In total, 1,581 serum arbekacin concentrations were measured (primarily from routine patient care) and used to perform the present pharmacokinetic analysis. Drug concentration-time data were well described by a two-compartment open model. Factors influencing arbekacin pharmacokinetics were investigated using a nonlinear mixed-effect model analysis. The best-developed model showed that drug clearance (CL) was related to creatinine clearance (CLCR), age, and body weight (WT), as expressed by CL (liter/h) = 0.0319CLCR + (26.5/age) (CLCR < 80 ml/min) and CL (liter/h) = 0.0130 CLCR + 0.0342WT + (26.5/age) (CLCR ≥ 80 ml/min). The volume of distribution for the central and peripheral compartments was different in healthy subjects and infected patients, and this difference was more pronounced among disease types. The elderly subjects (aged 80 years or over) exhibited, on average, a 19% greater volume for the central compartment. The volumes for the peripheral compartment were 50.6 liters in patients with pneumonia and 24.3 liters in patients with sepsis. The population pharmacokinetic parameters of arbekacin obtained here are useful for optimal use of this aminoglycoside in the treatment of MRSA-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=33750589806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750589806&partnerID=8YFLogxK

U2 - 10.1128/AAC.00420-05

DO - 10.1128/AAC.00420-05

M3 - Article

C2 - 17065621

AN - SCOPUS:33750589806

VL - 50

SP - 3754

EP - 3762

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -